Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 34 patient service centers in New York and New Jersey; and a free-standing ÂSTAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.
IPO Year: 1988
Exchange: NYSE
Website: enzo.com
4 - ENZO BIOCHEM INC (0000316253) (Issuer)
4 - ENZO BIOCHEM INC (0000316253) (Issuer)
4 - ENZO BIOCHEM INC (0000316253) (Issuer)
4 - ENZO BIOCHEM INC (0000316253) (Issuer)
4 - ENZO BIOCHEM INC (0000316253) (Issuer)
4 - ENZO BIOCHEM INC (0000316253) (Issuer)
4 - ENZO BIOCHEM INC (0000316253) (Issuer)
4 - ENZO BIOCHEM INC (0000316253) (Issuer)
4 - ENZO BIOCHEM INC (0000316253) (Issuer)
3 - ENZO BIOCHEM INC (0000316253) (Issuer)
8-K - ENZO BIOCHEM INC (0000316253) (Filer)
10-K - ENZO BIOCHEM INC (0000316253) (Filer)
8-K - ENZO BIOCHEM INC (0000316253) (Filer)
8-K - ENZO BIOCHEM INC (0000316253) (Filer)
8-K - ENZO BIOCHEM INC (0000316253) (Filer)
8-K - ENZO BIOCHEM INC (0000316253) (Filer)
11-K - ENZO BIOCHEM INC (0000316253) (Filer)
10-Q - ENZO BIOCHEM INC (0000316253) (Filer)
8-K - ENZO BIOCHEM INC (0000316253) (Filer)
8-K - ENZO BIOCHEM INC (0000316253) (Filer)
SC 13G/A - ENZO BIOCHEM INC (0000316253) (Subject)
SC 13G/A - ENZO BIOCHEM INC (0000316253) (Subject)
SC 13G - ENZO BIOCHEM INC (0000316253) (Subject)
SC 13D/A - ENZO BIOCHEM INC (0000316253) (Subject)
SC 13D - ENZO BIOCHEM INC (0000316253) (Subject)
SC 13G/A - ENZO BIOCHEM INC (0000316253) (Subject)
SC 13D/A - ENZO BIOCHEM INC (0000316253) (Subject)
SC 13D/A - ENZO BIOCHEM INC (0000316253) (Subject)
SC 13D/A - ENZO BIOCHEM INC (0000316253) (Subject)
SC 13G/A - ENZO BIOCHEM INC (0000316253) (Subject)
FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock. Full Year Highlights The Company's revenues in the 2024 period of $31.9 million improved year-over-year by 3%. Enzo's sales to its industrial customers, which includes biotech and pharmaceutical companies, increased 46% driven by our drug development and cell and gene therapy focus.The Company's FY24 gross margin was 46%. The prio
FARMINGDALE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced financial results for the fiscal third quarter ended April 30, 2024. Third Quarter Highlights The Company's Life Science division's third-quarter revenue of $8.0 million improved year-over-year by 7%, marking four consecutive quarters of revenue growth compared to the prior year quarterly periods. Revenue for the nine months ended April 30, 2024 of $24.4 million improved 10% compared to the same year-to-date period in the prior year. Focus on the Company's drug development tools segment is a key driver of the year-to-date growth.The Life Science division's third-qu
FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced financial results for the second quarter ended January 31, 2024. Second Quarter Highlights The Company's Life Science division's second-quarter revenue of $8.5 million improved year-over-year by 14%. During the 2024 period, we experienced a 25% revenue increase in the United States, driven by increased product demand in the drug development and cell and gene therapy market segments. Revenue for the six months ended January 31, 2024 of $16.4 million improved 12% compared to the same period in the prior year.The Life Science division's second-quarter gross m
FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company"), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments. Summary of the Fiscal Year 2023 Annual Shareholder Meeting Proposals Proposal One – The shareholders elected Kara Cannon, Steven J. Pully, Bradley L. Radoff, and Mary Tagliaferri, M.D. to the Company's Board of Directors to hold office for a term ending as of our Fiscal 2024 annual meeting of shareholders, and until each such director's successor is elected and qualified. Proposal Two – The shareholders did not approve, by a non
FARMINGDALE, NY, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced financial results for the first quarter ended October 31, 2023. First Quarter Highlights The Company's Life Sciences division's first quarter revenue improved year-over-year by 10% driven by increased demand in multiple product areas, and stability in our multi-pronged channel to market approach. The Life Sciences division's first quarter gross margin was 44.3%, which improved sequentially and year-over-year by approximately 900 basis points. This favorable result was driven by cost containment initiatives, manufacturing improvements and realignmen
FARMINGDALE, NY, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced financial results for the fourth quarter ended July 31, 2023, and the fiscal year ended July 31, 2023, and also provided a general business update. Fourth Quarter Highlights In July 2023, Enzo Biochem closed on the sale of assets used in the operation of Enzo Clinical Labs for a cash purchase price of $113,250,000, resulting in the full divestment of Enzo's clinical laboratory operations.Enzo Life Sciences' fourth quarter revenue improved sequentially by 20%, and year over year by 13%, driven by increased demand in multiple product areas and certain
FARMINGDALE, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or "the Company"), a leading life sciences company, announced today that Steven J. Pully has been appointed to the Company's Board of Directors effective October 26, 2023. Mr. Pully will assume the role of Chairperson of the Board, and Chair of the Audit Committee as well. "In 2023, Enzo completed the divestiture of Enzo Clinical Labs, Inc. and focused its strategy on growing the life sciences division," said Kara Cannon, Enzo's Chief Executive Officer. "Steve brings a unique portfolio of legal, corporate governance, and financial skills to our Board of Directors, and his experience will facilitate h
Highlights the Destruction of 70% in Stockholder Value Under Garry Mauro's 10-Year Reign as Chairman Notes the Radoff-Sudbury Group's Aligned and Highly Qualified Director Candidates Collectively Own Significantly More Stock than the Entire LifeVantage Board and are Committed to Acting in Stockholders' Best Interests Urges Stockholders to Vote for the Radoff-Sudbury Group's Director Candidates – Dayton Judd, Michael Lohner and Bradley L. Radoff – on the BLUE Proxy Card Ahead of LifeVantage's Upcoming Annual Meeting Bradley L. Radoff and Sudbury Capital Fund, LP (together with their affiliates, the "Radoff-Sudbury Group" or "we"), who collectively own approximately 12.8% of the outstan
FARMINGDALE, NY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) announced today that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo's Chief Operating Officer, Kara Cannon, assuming the role of interim CEO. "We thank Hamid for the commitment he has brought to Enzo Biochem, Inc." Chairperson of the Board Mary Tagliaferri, MD stated, "Hamid successfully led the Company through the divestiture of Enzo Clinical Lab, Inc. We wish him well in all his future endeavors and are excited to focus on the life sciences division. We are confident in Kara to lead th
Significant value unlocked for Enzo shareholders with continued focus on life sciences. FARMINGDALE, NY, July 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has closed a transaction to sell certain assets of Enzo's Clinical laboratory division (Enzo Clinical Labs) to Laboratory Corporation of America Holdings (Labcorp) (NYSE:LH) pursuant to an Asset Purchase Agreement dated March 16, 2023, as amended July 3, 2023. ASSET SALE Enzo Biochem has completed the previously announced transaction to sell substantially all of the assets located in the New York metropolitan region used in the operation of Enzo Clinical Labs to Labcorp for an aggregat
FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company"), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments. Summary of the Fiscal Year 2023 Annual Shareholder Meeting Proposals Proposal One – The shareholders elected Kara Cannon, Steven J. Pully, Bradley L. Radoff, and Mary Tagliaferri, M.D. to the Company's Board of Directors to hold office for a term ending as of our Fiscal 2024 annual meeting of shareholders, and until each such director's successor is elected and qualified. Proposal Two – The shareholders did not approve, by a non
FARMINGDALE, NY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) announced today that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo's Chief Operating Officer, Kara Cannon, assuming the role of interim CEO. "We thank Hamid for the commitment he has brought to Enzo Biochem, Inc." Chairperson of the Board Mary Tagliaferri, MD stated, "Hamid successfully led the Company through the divestiture of Enzo Clinical Lab, Inc. We wish him well in all his future endeavors and are excited to focus on the life sciences division. We are confident in Kara to lead th
NEW YORK, NY, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company"), a leading biosciences and diagnostics company, today announced the appointment of Patricia Eckert, CPA, as interim Chief Financial Officer (CFO). Ms. Eckert's appointment follows the resignation of David Bench, who is departing the Company effective November 14, 2022 to pursue a new opportunity. "While bittersweet in light of David's departure, we are exceedingly pleased to have Patricia in position to advance into the position of interim CFO," remarked Hamid Erfanian, CEO of Enzo. "Patricia is exceptionally qualified given her years of experience and comprehensive knowledge of Enzo'
NEW YORK, NY, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company"), a leading biosciences and diagnostics company, today announced the addition of Matthew Kupferberg as the Company's in-house General Counsel. Mr. Hamid Erfanian, Chief Executive Officer of Enzo, stated, "We are excited to add someone of Matthew's caliber to our executive team. After a thorough search, he brings the expertise and proven success in managing the full range of legal business issues that represent an ideal fit for Enzo as we continue to execute on our strategic "focused growth" strategy. With this addition, we are continuing to bring new levels of experience and
NEW YORK, NY, March 28, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company"), a leading biosciences and diagnostics company, today announced two key appointments to its new management structure. The Company announced Kara Cannon has been named Chief Operating Officer from her previous role as Chief Commercial Officer and David Bench, current Chief Financial Officer, has been named to the additional roles of Senior Vice President, Treasurer, and Corporate Secretary, effective immediately. Enzo is actively engaged in a search to augment its executive team including adding a Vice President of Commercialization, Director of Regulatory Affairs, Director of Research &
Dr. Elazar Rabbani to remain Chairperson of the Board and will assume new role as Chief Scientific Officer NEW YORK, NY, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company"), a leading biosciences and diagnostics company, announced today the appointment of Hamid Erfanian as Chief Executive Officer. Following the succession plan announced in March and the engagement of Korn Ferry, Dr. Elazar Rabbani remains Chairperson of the Board of Directors and will assume the role of Chief Scientific Officer of the Company. Mr. Erfanian brings over 28 years of experience as a seasoned healthcare executive specializing in the diagnostic, medical devices, and
NEW YORK, NY, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that it has reviewed the position of Institutional Shareholder Services (“ISS”) regarding the Company's executive compensation approach for the fiscal year ended July 31, 2020. To acknowledge and address the issues within the ISS report, Dr. Elazar Rabbani, the Company’s Chairperson and CEO, has requested the Compensation Committee of the Company’s Board of Directors not to pay his previously announced bonus in cash. In lieu thereof, he has requested such bonus be paid in common stock of Enzo based on the closing price of th
FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock. Full Year Highlights The Company's revenues in the 2024 period of $31.9 million improved year-over-year by 3%. Enzo's sales to its industrial customers, which includes biotech and pharmaceutical companies, increased 46% driven by our drug development and cell and gene therapy focus.The Company's FY24 gross margin was 46%. The prio
Highlights the Destruction of 70% in Stockholder Value Under Garry Mauro's 10-Year Reign as Chairman Notes the Radoff-Sudbury Group's Aligned and Highly Qualified Director Candidates Collectively Own Significantly More Stock than the Entire LifeVantage Board and are Committed to Acting in Stockholders' Best Interests Urges Stockholders to Vote for the Radoff-Sudbury Group's Director Candidates – Dayton Judd, Michael Lohner and Bradley L. Radoff – on the BLUE Proxy Card Ahead of LifeVantage's Upcoming Annual Meeting Bradley L. Radoff and Sudbury Capital Fund, LP (together with their affiliates, the "Radoff-Sudbury Group" or "we"), who collectively own approximately 12.8% of the outstan
FARMINGDALE, NY, April 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo Biochem" or the "Company"), a leading biosciences and diagnostics company, today announced that its special meeting of shareholders (the "Special Meeting") to consider and vote on a proposal to approve the sale (the "Asset Sale") of substantially all the assets and assignment of certain liabilities of its clinical laboratory business to Laboratory Corporation of America Holdings, a Delaware corporation ("Labcorp") and adopt the Asset Purchase Agreement, dated as of March 16, 2023 (as such agreement may be amended from time to time, the "Asset Purchase Agreement"), by and among the Company, Enzo Clinic
- Enzo Life Sciences reports revenue of $7.1 million and 9% growth in Q1 FY 2023, excluding FX - Engagement with investment bank to provide advisory services including the evaluation of strategic alternatives for the Company is progressing well. - Continuing to make progress in market expansion of the current product portfolio, commercialization of the Company's offerings, and optimization of the clinical service segment. Conference call and live webcast scheduled for tomorrow, Tuesday, December 13, 2022 at 8:30 am (ET) FARMINGDALE, N.Y., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported operating res
Conference Call and Webcast Scheduled for December 13th, 8:30 AM ET New York, NY, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report first quarter fiscal 2023 financial and operating results after the market close on Monday, December 12, 2022. The Form 10-Q filing will be followed by a live audio webcast and conference call the next day at 8:30 AM ET. To participate in the conference call, please dial the following numbers prior to the start of the call or click the webcast link below to participate over the internet: Tuesday, December 13th @ 8:30 am ET Domestic
NEW YORK, NY, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company"), a leading biosciences and diagnostics company, today announced that its Annual Shareholders' Meeting will be held on January 31, 2023. Shareholders must submit proposals and/or director nominations in connection with meeting no later than November 18, 2022 to be considered timely. About Enzo Biochem Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company,
- Enzo Life Sciences reports revenue of $32.6 million and 8% growth in FY 2022, net of FX - Company successfully launched AMPIVIEW™ gene expression platform powered by LoopRNA™ ISH technology - Continues to engage with previously announced investment bank to provide advisory services including the evaluation of strategic alternatives for the Company - Under the leadership of a new CEO, Enzo has been reorganized to leverage on our ‘focused return' strategy including the appointment of new executive management and augmenting the sales team to position the Company for continued growth in a cost-effective manner Conference call and live webcas
Conference Call and Webcast Scheduled for October 14, 2022, 8:30 am ET NEW YORK, NY, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report fourth quarter 2022 financial results on Friday, October 14, 2022, premarket. The announcement will be followed by a live audio webcast and conference call the same day at 8:30 am Eastern Time. Please see additional details below: Friday, October 14th @ 8:30 am ETDomestic: 877-407-0792International: 201-689-8263Conference ID: 13733235 Webcast: Registration Link -- Click Here About Enzo Biochem Enzo Biochem
Third quarter revenue of $26.2 million declined sequentially and year over year due to the anticipated waning of COVID-19 volumes and the economic shutdowns in Asia Received approval from New York State Department of Health for its AMPIPROBE® HPV Molecular Diagnostic tests available on the GENFLEX® platform, as well as approvals on additional sample types around chlamydia, gonorrhea and trichomonas Appointed and hired several new executive management team members in the quarter to position the Company for continued growthEngaged world class investment bank to provide advisory services including the evaluation of strategic alternatives for the Company, its Enzo Clinical Lab and Enzo Life Scie
NEW YORK, NY, June 06, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report third quarter 2022 financial results on Thursday, June 9, 2022, after the market close. The announcement will be followed by a live audio webcast and conference call on Friday, June 10, 2022 at 8:30 am Eastern Time. Please see additional details below: Friday, June 10th @ 8:30 am ETDomestic: 877-407-0792International: 201-689-8263Conference ID: 13730182 Webcast: Registration Link -- Click Here About Enzo Biochem Enzo Biochem is a pioneer in molecular dia
Shares of PriceSmart, Inc. (NASDAQ:PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for its second quarter. The company reported quarterly earnings of $1.31 per share, beating market estimates of $1.25 per share. PriceSmart’s quarterly sales came in at $1.29 billion versus expectations of $1.28 billion, according to data from Benzinga Pro. PriceSmart shares surged 4.6% to $86.90 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Marin Software Incorporated (NASDAQ:MRIN) shares rose 76.1% to $0.5054 in pre-market trading after the company announced upgrades to its Microsoft Corp (NASDAQ:MSFT) adver
With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: Wall Street expects HEICO Corporation (NYSE:HEI) to report quarterly earnings at 68 cents per share on revenue of $898.25 million after the closing bell. HEICO shares fell 0.6% to $181.85 in after-hours trading. EMCOR Group, Inc. (NYSE:EME) said Mark A. Pompa, Executive Vice President and Chief Financial Officer, and R. Kevin Matz, Executive Vice President Shared Services, will step down from their respective positions, effective April 1, 2024. The company named Jason R. Nalbandian as Senior Vice President and CFO. EMCOR shares fell 0.9% to $216.64 in th
Enzo Biochem (NYSE:ENZ) reported quarterly losses of $(0.13) per share. This is a 40.91 percent increase over losses of $(0.22) per share from the same period last year.
Gainers SILO Pharma (NASDAQ:SILO) shares increased by 36.2% to $2.22 during Tuesday's pre-market session. The company's market cap stands at $6.9 million. TRACON Pharma (NASDAQ:TCON) shares increased by 30.02% to $0.23. The market value of their outstanding shares is at $7.0 million. Fresh2 Group (NASDAQ:FRES) shares increased by 28.4% to $1.22. The market value of their outstanding shares is at $17.9 million. Brainstorm Cell (NASDAQ:BCLI) shares increased by 22.03% to $0.22. The company's market cap stands at $10.7 million. TC BioPharm (Holdings) (NASDAQ:TCBP) shares moved upwards by 19.23% to $0.62. The company's market cap stands at $5.8 million. Connect Biopharma Hldgs (NASDAQ:CNTB
Enzo Biochem, Inc. (NYSE:ENZ) announced today that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo's Chief Operating Officer, Kara Cannon, assuming the role of interim CEO. "We thank Hamid for the commitment he has brought to Enzo Biochem, Inc." Chairperson of the Board Mary Tagliaferri, MD stated, "Hamid successfully led the Company through the divestiture of Enzo Clinical Lab, Inc. We wish him well in all his future endeavors and are excited to focus on the life sciences division. We are confident in Kara to lead the Company forward during this transition. Kara is a sea
Gainers Aurora Acquisition Corp. (NASDAQ:AURC) shares jumped 192% to $30.54. Inpixon (NASDAQ:INPX) gained 117% to $0.33 after the company agreed to merge with XTI Aircraft Company. Electra Battery Materials Corporation (NASDAQ:ELBM) shares shot up 71.5% to $2.11 after jumping 22% on Monday. Electra Battery Materials said its battery grade cobalt supply agreement with LG Energy Solution has been extended and expanded from terms initially announced in Sept. 2022. Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) shares gained 35.3% to $4.68 after the company announced US patent for novel prodrugs of mebendazole and their use in treating cancer. Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) climb
Gainers Bullfrog AI Hldgs (NASDAQ:BFRG) stock moved upwards by 45.4% to $5.03 during Tuesday's pre-market session. The company's market cap stands at $30.6 million. Enzo Biochem (NYSE:ENZ) shares rose 16.91% to $1.59. The market value of their outstanding shares is at $79.0 million. Aravive (NASDAQ:ARAV) shares moved upwards by 14.09% to $1.7. The market value of their outstanding shares is at $101.7 million. Novan (NASDAQ:NOVN) stock increased by 11.5% to $0.14. The market value of their outstanding shares is at $3.9 million. Biotricity (NASDAQ:BTCY) stock rose 10.72% to $3.51. The market value of their outstanding shares is at $30.7 million. Alpha Tau Medical (NASDAQ:DRTS) stock move
Gainers Electra Battery Materials Corporation (NASDAQ:ELBM) shares surged 59% to $1.96 in pre-market trading after jumping 22% on Monday. Electra Battery Materials said its battery grade cobalt supply agreement with LG Energy Solution has been extended and expanded from terms initially announced in Sept. 2022. Carmell Therapeutics Corporation (NASDAQ:CTCX) rose 52% to $5.30 in pre-market trading after falling over 36% on Monday. Yoshiharu Global Co. (NASDAQ:YOSH) shares gained 50.5% to $0.9620 in pre-market trading. AppHarvest, Inc. (NASDAQ:APPH) gained 25% to $0.1128 in pre-market trading. AppHarvest shares declined 73% on Monday after the company announced Chapter 11 filing to sup